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Abstract
Background: Recent methodologic evidence suggests that lack of blinding in randomized trials can result in
under- or overestimation of the treatment effect size. The objective of this study is to quantify the extent of bias
associated with blinding in randomized controlled trials of oral health interventions.
Methods: We selected all oral health meta-analyses that included a minimum of five randomized controlled trials.
We extracted data, in duplicate, related to nine blinding-related criteria, namely: patient blinding, assessor blinding,
care-provider blinding, investigator blinding, statistician blinding, blinding of both patients and assessors, study
described as “double blind”, blinding of patients, assessors, and care providers concurrently, and the
appropriateness of blinding. We quantified the impact of bias associated with blinding on the magnitude of effect
size using a two-level meta-meta-analytic approach with a random effects model to allow for intra- and inter-meta-
analysis heterogeneity.
Results: We identified 540 randomized controlled trials, included in 64 meta-analyses, analyzing data from 137,957
patients. We identified significantly larger treatment effect size estimates in trials that had inadequate patient
blinding (difference in treatment effect size = 0.12; 95% CI: 0.00 to 0.23), lack of blinding of both patients and
assessors (difference = 0.19; 95% CI: 0.06 to 0.32), and lack of blinding of patients, assessors, and care-providers
concurrently (difference = 0.14; 95% CI: 0.03 to 0.25). In contrast, assessor blinding (difference = 0.06; 95% CI: -0.06 to
0.18), caregiver blinding (difference = 0.02; 95% CI: -0.04 to 0.09), principal-investigator blinding (difference = − 0.02;
95% CI: -0.10 to 0.06), describing a trial as “double-blind” (difference = 0.09; 95% CI: -0.05 to 0.22), and lack of an
appropriate method of blinding (difference = 0.06; 95% CI: -0.06 to 0.18) were not associated with over- or
underestimated treatment effect size.
Conclusions: We found significant differences in treatment effect size estimates between oral health trials based on
lack of patient and assessor blinding. Treatment effect size estimates were 0.19 and 0.14 larger in trials with lack of
blinding of both patients and assessors and blinding of patients, assessors, and care-providers concurrently. No
significant differences were identified in other blinding criteria. Investigators of oral health systematic reviews
should perform sensitivity analyses based on the adequacy of blinding in included trials.
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Background
As evidence-based practice has grown over the past two
decades, there has been a consistent generation of new
randomized controlled trials (RCTs) and systematic re-
views in medicine and dentistry. Currently, thousands of
RCTs and meta-analyses of these trials are published
every year to guide healthcare professionals in their
evidence-based decisions in clinical practice. In the field
of dentistry alone, nearly 50 new clinical trials and 20
systematic reviews are published every month [1–3].
These trials and systematic reviews, in turn, support
much of the treatment modalities and treatment recom-
mendations in dental practice based on the current best-
identified evidence. While RCTs, the building blocks of
systematic reviews and meta-analyses, are considered to
provide reliable evidence for dental decision making,
RCTs are susceptible to bias (underestimation or over-
estimation of treatment effect size (ES) estimates) due to
limitations in their design, conduct, and reporting [4, 5].
For results and outcomes of RCTs to be generalizable
and valid to specific patient subsets, they need to be
properly designed, carefully conducted, and accurately
reported to a standard that warrants the implementation
of their results [4, 6].
Blinding (or “masking”) has been recognized as an im-
portant criterion of high methodological quality, particu-
larly with respect to internal validity of RCTs [7].
Blinding is broadly used in a trial to prevent perform-
ance bias (blinding of participants and care providers)
and detection bias (blinding of assessors) [8–10]. Blind-
ing can be applied at numerous levels of a trial, includ-
ing participants, outcome assessors, care providers, data
analysts, or other personnel. Thus, several terms (e.g.,
single-, double-, or triple-blind) have been used to
describe blinding types [6, 11, 12]. However, the use of
these terms has been inconsistent among research
groups, and this contributed to conceptual and oper-
ational ambiguity. While appropriate blinding can re-
duce performance and detection biases, it is not always
feasible to apply blinding in a trial, particularly in an
RCT that involves surgical or device interventions such
as oral surgery and orthodontics, as participants are
often aware of the type of intervention they are receiv-
ing. The appropriateness of blinding depends on factors
such as type of outcome examined (e.g., objective vs.
subjective) [10] and type of intervention applied (e.g.,
surgical vs. drug) among others. For example, it is more
difficult to implement blinding in RCTs of surgical inter-
ventions than to implement blinding in RCTs of drug
interventions in which trial investigators can use placebo
medications to attain adequate blinding [13].
Published meta-epidemiological studies focused on the
blinding domain have found potential associations be-
tween treatment ESs and blinding of participants [14–19],
care providers [15–17, 19], assessors [15, 17–21], and
“double blinding” [22, 23]. While those meta-
epidemiological investigations were conducted within nu-
merous health fields, the value of their conclusions may
be limited, based on numerous factors, when generalized
to other healthcare fields. These factors include a failure
to evaluate continuous outcomes because of a preference
for assessing dichotomous outcomes [15, 21, 23], emer-
gence of inconsistent methodological findings associated
with treatment ESs [15, 17, 22], and the study being
“underpowered” [24] by lacking adequate sample size,
which is needed to properly quantify bias in RCTs. More
notably, meta-epidemiological studies have reported that
the extent of bias in the treatment ES associated with
blinding varied across different medical fields as well as
across different types of intervention [17, 24].
To date, no meta-epidemiological study has examined
bias related to blinding in RCTs within any oral health
subspecialties or scope of practice in dentistry. There-
fore, it is unclear whether the previously mentioned con-
clusions hold true in the field of oral health research
where blinding is sometimes difficult or not feasible,
especially in oral health RCTs involving surgical or
device interventions, such as orthodontic trials.
Thus, our specific research questions were: (1) Do oral
health RCTs with adequate blinding of participants, out-
come assessors, and health care providers yield different
treatment ESs than trials with lack or unclear blinding?
(2) Do specific nonmethodological meta-analysis charac-
teristics (e.g., dental specialty, type of treatment, type of
outcome [objective vs. subjective], magnitude of the
treatment ES estimate, heterogeneity of meta-analysis)
modify the association between blinding and treatment
ES estimates? Findings generated from this work could
be used to improve the conduct and reporting of oral
health RCTs.
Methods and analysis
This study is part of a large meta-epidemiological study
that investigates the association between methodological
characteristics and treatment ES estimates in oral health
RCTs. The protocol for this meta-epidemiological study
was registered on PROSPERO (CRD42014014070), and
published a priori [25].
Literature search
We conducted a comprehensive literature search using
six electronic databases (PubMed, MEDLINE, EMBASE,
ISI Web of Science, Evidence-Based Medicine Reviews–
Cochrane Database of Systematic Reviews, and Health
STAR) from database inception to May 2014. A health
sciences information specialist assisted in planning the
search strategy which included a combination of index
terms and keywords related to systematic reviews and
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oral health. The search strategy for each database can be
found in Additional file 1: Appendix 2. We also searched
the American Dental Association (ADA)–Evidence-
based Dentistry database [26] and hand-searched the
reference lists of potentially relevant studies identified in
the main search, which focused on quality of systematic
reviews in oral health. We did not restrict searches to
English language nor did we limit them by other means.
Inclusion and exclusion criteria
Two independent reviewers (H.S., M.A.) with dental
research and clinical backgrounds screened titles and ab-
stracts retrieved. Abstracts deemed to meet inclusion
criteria were selected, and then full text reports of these
and those that lacked sufficient information in the ab-
stract were retrieved for screening. The same assessors
independently determined final eligibility of full texts;
discrepancies were resolved through consensus.
We included meta-analyses if they met the following pre-
defined eligibility criteria: the meta-analysis (1) was in the
field of oral health research and examined a therapeutic
intervention related to treatment, prevention, or rehabilita-
tion of dental, oral, or craniofacial diseases [27, 28]; and (2)
examined at least one continuous outcome and included a
minimum of five randomized trials with quantitative data
of treatment ES estimates.
We subsequently selected RCTs included in the
selected meta-analyses that met the following predefined
eligibility criteria: (1) the design was reported to be an
RCT where findings were reported in a way that allowed
for calculation of treatment ES estimates; (2) the com-
parison was between an intervention versus a placebo,
with no treatment control, or standard care (trials with a
comparison of one active intervention versus another
active intervention and there was no clear direction of
which intervention was superior were excluded); and (3)
the trials examined a therapeutic intervention related to
a dental specialty recognized by the American Dental
Association (ADA) [28].
Data extraction
A panel of five reviewers from diverse health research
areas (H.S., C.H., J.S., J.F., S.A-O.) carried out data ex-
traction. To ensure consistency during data extraction,
two team members (H.S.; S.A-O) conducted reviewer
training; the review panel evaluated 10 randomized trials
not included in the final set of trials and then discussed
them to achieve consistency. A similar reviewer training
process was conducted in other studies performed by
the same research team [29, 30]. Data extraction was
performed in duplicate, that is, two assessors independ-
ently carried out data extraction, with consensus meet-
ings employed to resolve any disagreement. One
assessor with an oral health research background (H.S.)
performed complete data extraction (n = 540, 100%)
while another assessor (either C.H., J.S., or J.F.) with a
health sciences (non-oral health) research background
acted as a second assessor. The two assessors conferred
with a third assessor (S.A-O.) if agreement could not be
reached, to achieve complete consensus. Only consensus
data were used for statistical analyses. A structured and
pilot-tested data extraction template designed in a
Microsoft Office Access database was used for data
extraction.
The primary outcome reported for each review was
used as the primary outcome for our analysis. Alterna-
tively, the primary outcome for the analysis was deter-
mined as the outcome associated with the meta-analysis
that involved the largest number of trials (in case the
review’s primary outcome was binary, not clearly stated,
or the quantitative analysis associated with the outcome
included less than five trials). Details from each included
randomized trial and meta-analysis were extracted; the
following elements were extracted: means, standard
deviations, sample sizes, publication year, dental spe-
cialty (e.g., dental public health, endodontics, periodon-
tics, oral medicine and oral pathology, oral and
maxillofacial surgery, prosthodontics and restorative
dentistry, orthodontics and dentofacial orthopaedics,
and pediatric dentistry), primary outcome assessed, type
of comparison in a review, number of included trials in
a review, trial design (e.g., parallel, split-mouth, cross-
over, and factorial), type of outcome in a trial (e.g., drug
vs. nondrug or subjective vs. objective [23]), and number
of centers in a trial (e.g., multicenter vs. single center).
To classify the type of comparison, we used the classifi-
cation of the comparison implemented in the quantita-
tive analysis reported in the review (e.g., treatment vs.
control).
To assess risk of bias associated with blinding in the
selected randomized trials, we applied nine blinding-
based criteria (see Table 1), namely: patient blinding
(blinding of participants allocated to interventions), as-
sessor blinding (blinding of data collectors), care-
provider blinding (blinding of dental clinicians and/or
therapists who provided the interventions), investigator
blinding (blinding of the principal investigator), statisti-
cian blinding (blinding of the data analyst), blinding of
both patients and assessors, study described as “double
blind” (by trial investigators), blinding of patients, asses-
sors, and care providers concurrently, and the appropri-
ateness of blinding (blinding that was properly
implemented within the trial’s components according to
the primary outcome).
We scored each item following the definitions and
methods for each criterion in the quality assessment
tools that were found to be valid and most commonly
used in health research [7, 31–38]. We established our
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Table 1 Guidelines for quality assessment of included trials [7, 31–37, 63]
Items /Definitions Yes No Unclear
Performance Bias
Patient blinding [39]:
Was knowledge of the allocated
intervention adequately prevented
during the study?
“Blinding of patients is a must when
outcomes are subjective or
self-reported. When Outcomes are
measured by an assessor, then
assessors should be blinded to group
allocation. When Outcomes are
automated (there is no assessor
involved) then, blinding of participants
or assessors is not an issue.”
Any one of the following:
No blinding or incomplete
blinding, but the review authors
judge that the outcome is not
likely to be influenced by lack of
blinding (Automated outcome or
administrative); Blinding of
participants and key study personnel
ensured, and unlikely that the blinding
could have been broken; Objectives
automatized outcomes coming from
databases or hospital register office.
Any one of the following:
No blinding or incomplete
blinding, and the outcome
is likely to be influenced by
lack of blinding;
Blinding of key study
participants and personnel
attempted, but likely that the
blinding could have been
broken, and the outcome is
likely to be influenced by lack
of blinding.
Any one of the following:
Insufficient information to
permit judgement of ‘Low
risk’ or ‘High risk’;
The study did not address
the issue of blinding.
Blinded therapist/care-provider The study describes in the title,
abstract, or text that the therapists/
care-providers were blinded. The
blinding was appropriate.
The study describes in the
title, abstract, or text that the
therapists/care-providers
were not blinded, or because
of the nature of the
intervention (e.g., exercise
prescription or supervision,
etc.), the therapist could not
be blinded.
There is insufficient
information to permit a
judgment.
Blinded principal-investigator The study describes in the title,
abstract, or text that the investigator
was blinded. The blinding was
appropriate.
The study describes in the
title, abstract, or text that the
investigator was not blinded.
There is insufficient
information to permit a
judgment.
Blinded statistician The study describes in the title,
abstract, or text that the statistician
was blinded. The blinding was
appropriate.
The study describes in the
title, abstract, or text that the
statistician was not blinded.
There is insufficient
information to permit a
judgment.
Detection Bias
Assessor blinding [39]:
Was knowledge of the allocated
intervention adequately prevented
during the study?
Detection bias due to knowledge of
the allocated interventions
by outcome assessors.
Any one of the following:
No blinding of outcome assessment,
but the review authors judge that the
outcome measurement is not likely to
be influenced by lack of blinding;
Blinding of outcome assessment
ensured, and unlikely that the blinding
could have been broken.
Any one of the following:
No blinding of outcome
assessment, and the
outcome measurement is
likely to be influenced by
lack of blinding;
Blinding of outcome
assessment, but likely that
the blinding could have been
broken and the outcome
measurement is likely to be
influenced by lack of blinding.
Any one of the following:
Insufficient information to
permit judgement of ‘Low
risk’ or ‘High risk’;
The study did not address
the issue of blinding.
Detection/Performance Bias
Blinding of both patients and
assessors) [39]
Both patient blinding and assessor
blinding were judged as having low
risk of bias.
Both patient blinding and
assessor blinding were
judged as having high risk
of bias
Both patient blinding and
assessor blinding were judged as
having unclear risk of bias.
Study described as double blind “Double blind” is the description in
the study related to “blindness.”
Also, it should be stated that neither
the person doing the assessments nor
the study participants could identify
the intervention being assessed.
Not described as double
blind.
There is insufficient information
to permit a judgment.
blinding of patients, assessors, and
caregivers concurrently
Both patient blinding and assessor
blinding were judged as having low
risk of bias. Also, care-providers are
blinded.
Both patient blinding and assessor
blinding were judged as having high
risk of bias. Also, care-providers are
not blinded.
Both patient blinding and
assessor blinding were judged
as having unclear risk of bias.
Also, care-providers are
judged as “unclear”.
The method of blinding was
appropriate
The authors use the blinding
method appropriately.
There is no blinding or incomplete
blinding is performed, and the
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evaluation based on the chosen primary outcome of ana-
lysis, and employed a 3-level ordinal scoring scheme
comprised of “high, unclear, low” risk of bias [39] for
two domains (patient blinding and assessor blinding)
and “yes, no, unclear” [7] for the other five domains. See
Table 1 for further details of the blinding-based criteria
used in the study.
Moreover, we assessed whether each individual compo-
nent of a trial (participants, assessors, care-providers, stat-
isticians, or investigators) would be blinded to study
measurements: random assignment, hypothesis, details of
interventions, outcome measures, and outcome analysis.
Data analysis
To describe the blinding in the RCTs selected, we con-
ducted descriptive analyses including proportions and
percentages of study elements. To examine whether den-
tal RCTs with adequate blinding reported different treat-
ment ES estimates than trials with lack of blinding, we
conducted a two-level analysis using a meta-meta-
analytic approach with a random-effects model following
guidelines established by Sterne et al. [40]. This type of
analysis is reported to be the most effective to address
our research question, given that the methodological ap-
proach used for our meta-epidemiological analysis takes
into account heterogeneity between randomized trials,
within meta-analyses in a first step, and among meta-
analyses in a second step [41, 42]. We obtained raw data
for each trial from each meta-analysis and cross-checked
the numbers with the data reported in the primary trial.
For the “within meta-analyses level” (first level ana-
lysis), we obtained a standardized treatment ES estimate
for the primary outcome of each randomized trial, as
outlined by Cohen [43]. A negative treatment ES
estimate entailed a favourable effect of the tested inter-
vention. We obtained data from each selected random-
ized trial and meta-analysis. We considered a trial if it
was included in more than one meta-analysis, only once
(from the meta-analysis with the fewer number of trials).
We divided included trials, for each meta-analysis and
each randomized trial component, into two groups ac-
cording to the relevant quality criterion (e.g., participant
blinding, assessor blinding, care-provider blinding)—
those that adequately addressed the criterion and those
that did not (“no” or “unclear”). We calculated two treat-
ment ES estimates for each meta-analysis: the first corre-
sponded to the pooled treatment ES estimate from trials
including the characteristic of interest (e.g., patient
blinding) and the second corresponded to the pooled
treatment ES estimate from trials where the characteris-
tic of interest (e.g., no or unclear patient blinding) was
not met. We conducted inverse-variance random-effects
meta-analysis to derive pooled treatment ES estimates
for each meta-analysis, and calculated the DerSimonian
and Laird estimates of variance to determine heterogen-
eity between randomized trials [41]. Thus, for each
meta-analysis, we used meta-regression approaches to
derive the difference between pooled estimates from tri-
als with and without the characteristic of interest, as well
as its standard error. A negative difference in treatment
ES estimate implied that trials with the blinding-based
item yielded a more favourable treatment ES estimate
for the tested intervention.
For the “among meta-analyses level” (second level
analysis), we pooled findings of the previous analysis
(combined differences from all meta-analyses) to
describe the effect of each trial’s component across all
meta-analyses. We combined differences in treatment
ES estimates at this stage using inverse-variance
random-effects meta-analysis [41] to account for
between-meta analysis heterogeneity, and calculated
the DerSimonian and Laird estimates of variance to
determine heterogeneity between meta-analyses [41].
All p-values were two-sided.
Table 1 Guidelines for quality assessment of included trials [7, 31–37, 63] (Continued)
Items /Definitions Yes No Unclear
Blinding of participants/patients is a
“must” when outcomes are subjective
or self-reported.
When outcomes are measured by
an assessor, the assessors should be
blinded to group allocation.
Also, score “completely done” when
it is unlikely that the blinding could
have been broken and the
nonblinding of others is unlikely to
introduce bias. No blinding, but the
review authors judge that the
outcome and the outcome
measurement are not likely to be
influenced by lack of blinding.
Objectives automatized outcomes
coming from databases or hospital
register office.
outcome or outcome measurement
is likely to be influenced by lack of
blinding.
There is insufficient
information to permit a
judgment.
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To examine whether specific characteristics modify
the associations between blinding and the treatment ES
estimate, we stratified the analyses with interaction tests
based on Z scores according to the following factors:
type of outcome (objective vs. subjective), dental special-
ity (periodontal vs. other interventions, or dental public
health vs. other interventions), magnitude of the treat-
ment ES estimate (small, if > − 0.5 vs. large, if ≤ − 0.5),
and heterogeneity of the meta-analysis (low if τ2 < 0.06
vs. high if τ2 ≥ 0.06; the cut-off of τ2 = 0.06 roughly
amounts to a difference between the largest and the
smallest treatment ES estimate, where the smallest
treatment ES estimate = 1). We performed all analyses
using STATA statistical software version 14 (College
Station, TX: StataCorp LP). The analysis was conducted
by the principal investigator who was trained, and
supervised by a team member with extensive experience
in analyses of meta-epidemiological studies.
We calculated the sample size according to recom-
mendations in Hempel et al. [44] and Berkman et al.
[24]. From previous meta-epidemiological investigations
[30, 45, 46], we anticipated obtaining a difference in
treatment ES estimates of at least 0.15 (SE = 0.087)
between trials with and without quality criteria [45].
This magnitude of difference in treatment ES estimates
has been claimed to resemble nearly 1/4 to 1/2 of classic
treatment ES estimates for interventions in fields similar
to the field of dentistry [45]. Accordingly, we planned a
sample size of nearly 500 randomized trials included in
60 systematic reviews to demonstrate such a meaningful
difference. This is approximately two to three times the
number of trials included in previously published meta-
epidemiological investigations [18, 45, 47].
Results
Characteristics of selected systematic reviews and
included randomized trials
The updated database of dental, oral, and craniofacial
systematic reviews [45] included 1408 records (published
between 1991 and 2014) of which 152 systematic reviews
with meta-analyses were judged to be potentially rele-
vant; of these, 64 (32 Cochrane and 32 non-Cochrane
reviews) satisfied the eligibility criteria for the present
report. The complete list of excluded reviews is available
upon request.
Overall, the chosen meta-analyses were published
between 2002 and 2014 (median year of publication:
2010; interquartile range [IQR] 2006–2012), while the
median number of trials included in the meta-analyses
was six (IQR 6–10). A total of 540 trials analyzing
137,957 patients were considered for this study [48, 49].
The meta-analyses examined a therapeutic intervention
related to the fields of periodontics (36 reviews; 271
trials), dental public health and pediatric dentistry (10
reviews; 145 trials), oral medicine and pathology (11
reviews; 80 trials), oral and maxillofacial surgery (4 reviews;
26 trials), orthodontics and dentofacial orthopedics (2 re-
views; 12 trials), and restorative dentistry (1 review; 6 trials).
Approximately one-fifth of the trials were multicenter trials,
nearly one-third of the trials placebo-controlled (n = 204;
37.8%), and two-thirds of the trials examined were nondrug
(n = 359; 66.5%) or nonsurgical (n = 370; 68.5%) interven-
tions. The majority of trials used parallel design (n = 372;
68.9%), and one-quarter used split-mouth design (n = 126;
23.3%). Additional file 2: Appendix 1 provides further
details on characteristics of the chosen meta-analyses.
Blinding in dental randomized trials
Blinding of patients was judged as adequate (low risk of
bias) in 71.5% (n = 386) of the trials, and blinding of the
outcome assessment was judged as adequate (low risk of
bias) in 59.4% of the trials. Blinding of both patients and as-
sessors was judged as adequate in 72.8% of trials (n = 273),
and 76.5% (n = 117) of trials were assessed as adequate with
respect to blinding of patients, assessors, and care-
providers. Blinding of the assessor was reported in 59.4% of
trials (n = 321), while blinding of patients was unclear/not
reported in nearly half of trials (n= 279; 51.7%). Two-thirds
of trials were not described as double-blind (n = 358; 66.3%).
The method of blinding was appropriate in 53% of trials (n
= 286), while blinding of the principal investigator and statis-
tician was unclear/not reported in the vast majority of trials.
Tables 2 and 3 provide details of the blinding of individual
components (participants, assessors, principal investigators,
care-providers, and statisticians), and the level of blinding
(random assignment, hypothesis, details of intervention, and
data analysis) in RCTs of oral health interventions.
Impact of patient blinding on treatment effect size
estimate
Figure 1 displays a forest plot of the difference in treat-
ment ES estimates between trials with the presence and
lack of patient blinding. Twenty-eight meta-analyses,
including 275 trials that analyzed 109,753 patients, pro-
vided information for this meta-epidemiological analysis.
Results of the analysis showed that trials with inadequate
patient blinding had significantly larger treatment ES es-
timates (difference = 0.12, 95% confidence interval 0.00 to
0.23, p = 0.046). However, the impact of patient blinding
on treatment ES estimates stratified by other characteris-
tics of meta-analyses (heterogeneity of meta-analysis, type
of outcome, and dental speciality) was not statistically sig-
nificant for any of the characteristics (see Fig. 2a).
Impact of assessor blinding on treatment effect size
estimate
Figure 3 displays a forest plot of the difference in treatment
ES estimates between trials with a presence and a lack of
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assessor blinding. Forty-four meta-analyses, including 408
trials that analyzed 119,282 patients, provided information
for this meta-epidemiological analysis. Although assessor
blinding was not associated with a statistically significant
difference in treatment ES, trials with lack of assessor blind-
ing tended to inflate treatment ES estimates when compared
with trials with a presence of assessor blinding (difference =
0.06, 95% confidence interval − 0.06 to 0.18, p= 0.316). The
results of the stratified analyses show that none of the meta-
analyses characteristics had a statistically significant inter-
action with the treatment ES estimate (see Fig. 2b).
Impact of care-provider blinding on treatment effect size
estimate
Figure 4a displays a forest plot of the difference in treat-
ment ES estimates between randomized trials with a
presence and a lack of care-provider blinding. Eighteen
meta-analyses, including 408 trials that analyzed 109,383
patients, provided information for this meta-
epidemiological analysis. Care-provider blinding was not
associated with a statistically significant difference in treat-
ment ES estimates (difference = 0.02, 95% confidence
interval − 0.04 to 0.09, p = 0.509). The results of the strati-
fied analyses show that none of the meta-analyses charac-
teristics had a statistically significant interaction with the
treatment ES (see Fig. 2c).
Impact of principal-investigator blinding on treatment
effect size estimate
Figure 4b displays a forest plot of the difference in treat-
ment ES estimates between randomized trials with a
Table 2 Blinding in randomized trials of oral health interventions (N = 540)
Domain Risk of Bias Assessment, N (%)
Low Risk High Risk Unclear Risk
Blinding of patients/participants 386 (71.5) 7 (1.3) 147 (27.2)
Blinding of assessors 321 (59.4) 16 (3.0) 203 (37.6)
Blinding of both patients and assessorsa 273 (72.8) 7 (1.9) 95 (25.3)
Blinding of patients, assessors, and
care-providers concurrentlyb
117 (76.5) 7 (4.6) 29 (19.0)
Item Quality Assessment, N (%)
Yes No Unclear/Not reported
Study described as double-blind 181 (33.5) 358 (66.3) 1 (0.2)
Blinding of assessors 321 (59.4) 16 (3.0) 203 (37.6)
Blinding of patients 192 (35.6) 69 (12.8) 279 (51.7)
Blinding of therapists/care-providers 134 (24.8) 356 (65.9) 50 (9.3)
Blinding of principal investigator 33 (6.1) 10 (1.9) 497 (92.0)
Blinding of data analyst 9 (1.7) 3 (0.6) 528 (97.8)
Method of blinding appropriate 286 (53) 17 (3.1) 237 (43.9)
aDoes not equal 100% for overall, as the item was not applicable in 165 trials
bDoes not equal 100% for overall, as the item was not applicable in 387 trials
Table 3 Type of blinding in randomized trials of oral health interventions (N = 540); N (%)
Component Random allocation Hypothesis Details of intervention Outcome assessment Data analysis
Yes No Unclear/
NR
Yes No Unclear/
NR
Yes No Unclear/
NR
Yes No Unclear/
NR
Yes No Unclear/
NR
Participants 194
(35.93)
70
(12.96)
276
(51.11)
1
(0.19)
12
(2.22)
527
(97.59)
2
(0.37)
221
(40.93)
317
(58.70)
0
(0.0)
71
(13.15)
469
(86.85)
0
(0.0)
0
(0.0)
540
(100.0)
Assessors 322
(59.63)
15
(2.78)
203
(37.59)
1
(0.19)
11
(2.04)
528
(97.78)
8
(1.48)
37
(6.85)
495
(91.67)
NA NA NA 0
(0.0)
0
(0.0)
540
(100.0)
Principal
Investigator
32
(5.93)
10 (1.85) 498
(92.22)
0
(0.0)
0
(0.0)
540
(100.00)
0
(0.0)
0
(0.0)
540
(100.0)
1
(0.19)
2
(0.37)
533
(99.44)
0
(0.0)
0
(0.0)
540
(100.0)
Care-
providers
136
(25.19)
351
(65.00)
53
(9.81)
2
(0.37)
10
(1.85)
528
(97.78)
0
(0.0)
0
(0.0)
540
(100.0)
1
(0.19)
16
(2.96)
523
(96.85)
0
(0.0)
0
(0.0)
540
(100.0)
Statisticians 9
(1.67)
3
(0.56)
528
(97.78)
1
(0.19)
0
(0.0)
539
(99.81)
0
(0.0)
0
(0.0)
540
(100.0)
0
(0.0)
0
(0.0)
540
(100.0)
NA NA NA
NA not applicable, NR not reported
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presence and a lack of principal-investigator blinding.
Eighteen meta-analyses, including 162 trials that ana-
lyzed 59,757 patients, provided information for this
meta-epidemiological analysis. Principal-investigator
blinding was not associated with a statistically significant
difference in treatment ES estimates (difference = − 0.02,
95% confidence interval − 0.10 to 0.06, p = 0.641). Results
of stratified analyses show that none of the meta-
analyses characteristics had a statistically significant
interaction with the treatment ES (see Fig. 2d).
Impact of data-analyst blinding on treatment effect size
estimate
Due to the small number of trials with adequate blinding
of the data-analyst, meta-epidemiological analysis of the
data could not be performed for this criterion.
Impact of describing a trial as “double-blind” on
treatment effect size estimate
Figure 5 displays a forest plot of the difference in treat-
ment ESs between randomized trials with and without
reporting “double blinding.” Twenty-eight meta-analyses,
including 294 trials that analyzed 111,052 patients,
provided information for this meta-epidemiological ana-
lysis. Trials not described as double-blind tended to exag-
gerate treatment ES estimate compared to trials described
as double-blind. However, differences were not statistically
significant (difference = 0.09, 95% confidence interval − 0.
05 to 0.22, p = 0.203). The results of stratified analyses
showed that none of the meta-analyses characteristics had
a statistically significant interaction with the treatment ES
(see Fig. 6a).
Impact of blinding of both patients and assessors on
treatment effect size estimate
Figure 7a shows a forest plot of the difference in treat-
ment ES estimate in randomized trials with and without
blinding of both patients and assessors. Nineteen meta-
analyses, including 224 trials that analyzed 106,716
patients, provided information for this meta-
epidemiological analysis. Meta-epidemiological results
showed a statistically significant difference between the
treatment ES estimate in RCTs that implemented patient
and assessor blinding concurrently (difference = 0.19,
95% confidence interval 0.06 to 0.32, p = 0.004) and the
treatment ES estimate in randomized trials that did not
Fig. 1 Difference in treatment ES estimates between trials with presence and lack of patient blinding. A positive value (more than zero) across meta-analyses
indicates that treatment ES estimates are larger in trials that lack patient blinding compared to trials with adequate patient blinding. Diamond, difference in
treatment ES estimate between trial components across all meta-analyses; square, proportional to weight used in meta-meta-analysis; horizontal
arrow/line, a 95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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employ blinding of both patients and assessors. How-
ever, the impact of blinding of both patients and asses-
sors on treatment ES estimate stratified by examined
characteristics of meta-analyses was not statistically
significant for any of the characteristics (see Fig. 6b).
Impact of blinding of patients, assessors, and care-
providers concurrently on treatment effect size estimate
Figure 7b shows a forest plot of the difference in treat-
ment ES estimate between randomized trials with the
presence and lack of blinding of patients, assessors, and
care-providers concurrently. Ten meta-analyses, includ-
ing 151 trials that analyzed 99,293 patients, provided in-
formation for this meta-epidemiological analysis. Results
of the analysis showed that trials that did not implement
patient, assessor, and care-provider blinding had signifi-
cantly larger treatment ESs (difference = 0.14, 95% confi-
dence interval 0.03 to 0.25, p = 0.013) than trials that
implemented blinding of those three components. How-
ever, results of the stratified analyses show that none of the
examined meta-analyses characteristics had a statistically
significant interaction with the treatment ES (see Fig. 6c).
Impact of using an appropriate method of blinding on
treatment ES
Figure 8 shows a forest plot of the difference in treat-
ment ES estimates between trials with the presence and
lack of an appropriate method of blinding. Forty meta-
analyses provided information for this meta-
epidemiological analysis. Presence of an appropriate
a b
c d
Fig. 2 Difference in treatment ES estimates, stratified by meta-analyses characteristics, between: (a) trials with presence and lack of patient blinding; (b)
trials with presence and lack of assessor blinding; (c) trials with presence and lack of care-provider blinding; (d) trials with and without principal-investigator
blinding. Square, proportional to weight used in meta-meta-analysis; horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference
in treatment ES estimate
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method of blinding was not associated with a statistically
significant difference in treatment ES estimate, trials that
lacked an appropriate method of blinding tended to in-
flate treatment ES estimates compared to trials with an
appropriate method of blinding (difference = 0.06, 95%
confidence interval − 0.06 to 0.18, p = 0.325). The results
of the stratified analyses showed that differences in treat-
ment ES estimates between trials with the presence or
lack of appropriate blinding were significant (p < 0.02) in
meta-analyses with a large treatment benefit in overall
meta-analysis, but not in meta-analyses with a small
treatment benefit. However, none of the other consid-
ered factors (heterogeneity of meta-analysis, type of out-
come, and dental specialty) had a statistically significant
interaction with the treatment ES estimate (see Fig. 6d).
Discussion
Our investigation provides empirical evidence of the im-
pact of bias associated with nine blinding-based criteria
(related to patient, assessor, care-provider, and principal-
investigator blinding) on the treatment ES estimate. This
analysis is important to methodologists and researchers
in dental, oral, and craniofacial research. To our know-
ledge, this study is the first meta-epidemiological study
conducted in any medical or dental field that examines
continuous outcomes of the impact of blinding of both
patients and assessors and of patients, assessors, and
care-providers on treatment ES estimates in randomized
trials.
Our study shows significant differences in treatment
ES estimates in oral health RCTs based on different
types of blinding. For example, RCTs with lack of patient
and assessor blinding had significantly larger treatment
ES estimates compared to trials without lack of patient
and/or assessor blinding. Patient blinding and assessor
blinding were associated with inflated treatment ES esti-
mates (significant at the level of patient blinding), while
care-provider and principal-investigator blinding were
Fig. 3 Difference in treatment ES estimate between trials with presence and lack of assessor blinding. A positive value (more than zero) across
meta-analyses indicates that lack of assessor blinding inflates the treatment ES estimate when compared with trials with adequate assessor blinding.
Diamond, difference in treatment ES estimate between trial components across all meta-analyses; square, proportional to weight used in meta-meta-
analysis; horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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not related to inflated treatment ES estimates. Interest-
ingly, lack of blinding of both assessors and patients was
found to be associated with the largest overestimation in
treatment ES estimate (0.19). This measured magnitude
of bias represents approximately 1/3 of common treat-
ment ES estimates reported in oral health research [50],
such as clinical outcomes in periodontology [46]. The
fact that treatment ES estimates in oral health trials may
have been biased due to lack of blinding is concerning,
as clinical decision making related to recommended
dental treatments and modalities may therefore not be
based on valid findings.
The stratified analyses showed that the extent of bias
associated with lack of blinding was not significantly
associated with any other factor considered at the meta-
analysis level. This agrees with a recent study conducted
in the area of physical therapy, and is contrary to other
meta-epidemiological studies [51], which showed that
trials with subjective outcomes exaggerated treatment
ES estimates compared to trials with objective outcomes.
a
b
Fig. 4 Difference in treatment ES estimate between: (a) trials with presence and lack of care-provider blinding (a positive value across meta-analyses
indicates that the lack of care-provider blinding inflates the treatment ES estimate when compared with trials with adequate care-provider blinding);
(b) trials with presence and lack of principal-investigator blinding (a positive value across meta-analyses indicates that the lack of principal-investigator
blinding inflates the treatment ES estimate when compared with trials with adequate principal investigator blinding). Diamond, difference in treatment
ES estimate between trial components across all meta-analyses; square, proportional to weight used in meta-meta-analysis; horizontal arrow/line, a
95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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This could be due to having a small number of trials
with objective outcomes in our study, or to differences
between interventions in different medical disciplines.
Reports examining the impact of lack of blinding of
patient, therapist, or assessor on treatment ES estimates
were conducted in particular medical fields such as
physical therapy [19], thrombosis and cardiovascular
disease [15, 21], pediatrics [18], osteoarthritis [45], and
low-back pain [16]. The studies reported inconsistent
findings. The treatment ES estimate was smaller in trials
that employed patient blinding [15] or assessor blinding
[20, 21] in some studies, whereas in other studies the
treatment ES estimate was smaller in trials that lacked
patient [17] or assessor blinding [15]. However, an
association between the treatment ES estimate and the
presence or lack of blinding was not confirmed in some
studies [16, 45]. Furthermore, while the definition of
double blinding varied largely among the meta-
epidemiological studies with respect to the level of blind-
ing (patient, assessor, and care-provider blinding), a lack
of double blinding was found to be associated with
exaggerated treatment ES estimates in general [22, 23, 52].
The inconsistent findings might be due to the examination
of different types of outcome, intervention, and popula-
tion, to the implementation of different definitions of
quality assessment, and to the application of various stat-
istical and modeling approaches [24]. For example, Schulz
et al. [52] applied a multiple logistic regression model to
analyze data on binary outcomes from 250 trials included
in 33 meta-analyses; the definition of double blinding was
based on whether the trial’s conduct claimed to be
double-blinded. Egger et al. [22] defined “double blinding”
based on whether the trial was described as double-blind,
or included at least assessor blinding; the study analyzed
data from 304 trials included in 39 meta-analyses with
binary outcomes in several medical fields (infectious
diseases, neurology, among others).
Two recent studies [18, 19] that examined the associ-
ation between lack of blinding of patient, therapist, or
assessor, and treatment ES using continuous outcomes,
also reported inconsistent findings. One study assessed
the adequacy of patient and assessor blinding in 287
pediatric trials from 17 meta-analyses [18], and showed
no significant difference in treatment ESs between stud-
ies, based on potential bias related to lack of blinding.
Another study assessed 165 physical therapy trials
Fig. 5 Difference in treatment ES estimate between trials with presence and lack of “double-blinded” description. A positive value (more than
zero) across meta-analyses indicates that trials not described as “double-blinded” inflate the treatment ES estimate when compared with trials
described as “double blinded”. Diamond, difference in treatment ES estimate between trial components across all meta-analyses; square, proportional
to weight used in meta-meta-analysis; horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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included in 17 meta-analyses and found that trials with a
lack of patient or assessor blinding tended to underesti-
mate treatment ES estimate when compared with trials
with appropriate blinding (although, the differences were
not statistically significant) [19]. It should be noted that
in both studies, lack of significant results might be
accounted for by the small number of trials, precision of
the analyses performed, and/or examination of interven-
tions where blinding is not crucial or fundamental (i.e.,
outcomes are objective or automated with no assessor
involvement).
Because the concept of blinding is implemented at
multiple levels of a trial (e.g., patients, assessors, care
providers, data analysts, investigators), there is confusion
when describing the level of blinding implemented. For
example, “double blinding” or “triple blinding” may refer
to blinding at any two or three of the previous levels.
Failure to clearly report the levels that such terms refer
to leads to confusion. Investigators of RCTs conducted
in the field of dentistry need to implement and clearly
report blinding of patients, assessors, care providers,
data analysts, and other personnel when applicable, and
explicitly report on mechanisms used to achieve and
assure successful blinding, as recommended by the
Consolidated Standards of Reporting Trials (CONSORT)
statement. In addition, investigators of RCTs should
state the levels (e.g., patients, assessors, care providers)
and components (e.g. allocation, outcomes assessed,
details of interventions) they are referring to when they
describe blinding of a trial. In addition, they should
avoid using the terms “double” or “triple” blind trial
when reporting trial findings, and report who was
a b
c d
Fig. 6 Difference in treatment ES estimates, stratified by meta-analyses characteristics, between: (a) trials with presence and lack of “double-blinded”
description; (b) trials with and without blinding of both patients and assessors; (c) trials with and without blinding of patients, assessors, and care
providers concurrently; (d) trials with and without appropriate method of blinding. Square, proportional to weight used in meta-meta-analysis;
horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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blinded and to what components blinding was achieved,
so the reader can evaluate potential associated bias. As
well, editors and peer reviewers of dental journals should
require authors of randomized trials to adhere to the
CONSORT guidelines and insist on adequate conduct and
reporting of blinding in submitted randomized trials.
When we examined the association between double
blinding and treatment ES, we performed the analysis on
two different criteria: reporting of “double blinding” as a
term in a trial, and actual conduct of blinding of both
assessors and patients. Haahr and Hróbjartsson [53],
who examined a random sample of RCTs from the
Cochrane Central Register of Controlled Trials, sug-
gested that it is incorrect to assume blinding of a trial
participant based only on the term “double blind.” The
study found that blinding of patients, care providers, and
assessors was clearly described in only three (2%) of 200
blinded RCTs, while 56% of trials failed to describe
blinding status of any individual involved in a trial. That
study concluded that either patients, care providers, or
assessors were not blinded in one of five “double blind”
RCTs. Another trial study [54] showed that adequate
reporting of blinding was common in some medical
journals, and that inadequate reporting of blinding does
not necessarily entail a lack of actual blinding. For ex-
ample, it was reported that RCT authors frequently use
blinding, although they fail to describe its methods. For
instance, authors of RCTs failed to report the blinding
a
b
Fig. 7 Difference in treatment ES estimate between: (a) trials with and without blinding of both patients and assessors (a positive value, more than zero,
across meta-analyses indicates that lack of blinding of both patients and assessors inflates the treatment ES estimate when compared with trials with
adequate blinding of patients and assessors); (b) trials with and without blinding of patients, assessors, and care providers (a positive value, more than
zero, across meta-analyses indicates that lack of blinding of patients, assessors, and care providers inflates the treatment ES estimate when compared with
trials adequately blinded in the three components). Diamond, difference in treatment ES estimate between trial components across all meta-analyses;
square, proportional to weight used in meta-meta-analysis; horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference in
treatment ES estimate
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status of patients in 26% of trials, and patients were ac-
tually blinded in 20% of trials in which patients were not
reported to be blinded. Similar results were found in a
recent study by Kahan et al. [55], who reported that
blinding of outcome assessors is uncommonly used and
inadequately reported in a cohort of 258 trials published
in four high-impact medical journals.
An implication that can be drawn from our meta-
epidemiological work is that authors of systematic
reviews of oral health interventions should consider
excluding dental RCTs with lack of blinding from meta-
analyses, or at least perform sensitivity analyses on
included trials based on the adequacy of blinding. In all
instances, authors should consider the likely level of bias
associated with reported (or unreported) blinding status
when interpreting the findings of a quantitative analysis.
The above-mentioned implications should be consid-
ered with caution, particularly in oral health trials
involving surgical or device interventions (such as ortho-
dontic trials) where patient blinding is not feasible; in
this case, informing patients with details of the
intervention is required, and sometimes ethically com-
pulsory. While these RCTs are prone to biases, particu-
larly when the RCTs examine self-reported outcomes,
implementation of blinding in the conduct of these trials
is often unacceptable for ethical and practical reasons.
For example, in the case of trials comparing surgical in-
terventions to nonsurgical interventions (e.g., compari-
son of surgical removal of wisdom teeth versus retention
or conservative management), patients and surgeons
cannot be blinded. However, trialists may consider using
“expertise-based” trial design, whereby patients are allo-
cated to multiple surgeons and each surgeon performs a
single treatment [56]. While this design helps to
minimize performance bias related to surgeon blinding,
it does not ensure patient blinding [57]. Furthermore, in
trials where patients cannot be blinded (e.g., comparison
of manual versus electric toothbrushing), trialists may
consider using objective outcomes that have established
validity and reliability [56] or blind patients to trial’s
hypothesis. When blinding is feasible, trialists should
consider blinding as many trial components
Fig. 8 Difference in treatment ES estimate between trials with and appropriate method of blinding (a positive value, more than zero, across
meta-analyses indicates that lack of an appropriate method of blinding inflates the treatment ES estimate). Diamond, difference in treatment ES
estimate between trial components across all meta-analyses; square, proportional to weight used in meta-meta-analysis; horizontal arrow/line, a
95% confidence interval; solid vertical line, line of no difference in treatment ES estimate
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(participants, assessors, care-providers, statisticians,
investigators) as ethically and practically possible.
Based on this evidence, investigators of systematic
reviews conducted in dental, oral, and craniofacial trials
should perform sensitivity analyses based on the
adequacy of blinding in included trials. The potential
impact of blinding on bias in treatment ES suggests that
dental journal editors and reviewers should insist on
adequate blinding (when feasible) with respect to trial
conduct and reporting, in published trials’ reports.
Strengths and limitations of the study
This meta-epidemiological study provides an empirical
analysis of the association between treatment ES esti-
mates and bias, in the domain of oral health research.
The study has several limitations.
First, we examined published studies only (bias was
based on reported methodological characteristics), and
did not evaluate actual conduct of the RCTs. Accord-
ingly, data extraction and analyses were based on infor-
mation given by authors in published reports. This
approach, although widely used, limits the identification
of actual bias if trial authors do not adequately report
study elements.
Second, while there are many ways for an RCT
planned as blinded to become unblinded, [58] our study
did not use specific mechanisms to look for evidence of
unblinding, such as differential (across treatment
groups) incidences of specific adverse events that would
give away which patients received which interventions
and large baseline imbalances indicative of the type of
selection bias that may occur with unsuccessful alloca-
tion concealment [59, 60]. Also, our study did not look
at how many RCTs reported a valid and reliable method
of assessment of the success of blinding such as the
Berger-Exner test of selection bias [58]. Accordingly,
future RCTs should routinely conduct and report the
results of a valid and reliable method of assessing the
success of blinding (such as the Berger-Exner test) based
on the extent to which any unblinding led to selection
bias [61, 62].
Third, certain levels of heterogeneity are expected in
any meta-epidemiological examination of the impact of
bias on treatment ES estimates. Such studies analyse nu-
merous entities (meta-analysis, trials, and participants)
that have a distinct potential for heterogeneity [24]. By
applying a cautious methodology to data collection and
analysis in this study, and by assembling a large number
of meta-analyses and trials, study power was increased
and heterogeneity was reduced.
Fourth, because our study did not compare the same
treatment with different degrees of blinding, the identi-
fied evidence could lead to the conclusion that trials of
interventions where blinding is not feasible, such as sur-
gery or devices, have in general higher treatment ES esti-
mates. Future meta-epidemiological studies should
further investigate the above-mentioned concept.
Finally, this study did not assess the likely effects of
interactions with other design biases. Such an assess-
ment would have to include a multivariate analysis with
a larger number of meta-analyses and trials [17]. Future
meta-epidemiological assembling of a greater number of
meta-analyses and trials by synthesizing results from dif-
ferent disciplines and datasets should take other design
biases into account.
Conclusions
We found significant differences in treatment ESs
between oral health RCTs based on lack of patient and
assessor blinding. RCTs that lacked patient and assessor
blinding had significantly larger treatment ES estimates.
Treatment ES estimates were 0.19 and 0.14 larger in tri-
als with lack of blinding of both patients and assessors
and blinding of patients, assessors, and care-providers
concurrently. No significant differences were identified
in other blinding criteria. Future meta-epidemiological
assembling of a greater number of meta-analyses and tri-
als that takes other biases and different degrees of blind-
ing into account is needed.
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